Ubiquitin variants and uses therof as 53BP1 inhibitors

Patent metadata

Field	Value
Publication number	US-10808017-B2
Application number	US-201716073501-A
Country	US
Kind code	B2
Filing date	Jan 31, 2017
Priority date	Feb 1, 2016
Publication date	Oct 20, 2020
Grant date	Oct 20, 2020

Abstract

53BP1 inhibitors, compositions comprising the inhibitors and methods of using same are provided. The inhibitors can be used in combination with gene editing systems.

First claim

What is claimed is:

1. A polypeptide comprising the amino acid sequence of SEQ ID NO: 1 having the following modifications:
(a) a Leu at positions 2 and 62 of SEQ ID NO: 1, an Asp at position 64 of SEQ ID NO: 1, a Lys at position 66 of SEQ ID NO: 1, and a Pro at position 69 of SEQ ID NO: 1;
(b) a Leu at positions 2, 62 and/or 70 of SEQ ID NO: 1, an Asp at position 64 of SEQ ID NO: 1, a Lys at position 66 of SEQ ID NO: 1, and a Pro at position 69 of SEQ ID NO: 1;
(c) a Leu at position 2 of SEQ ID NO: 1, an Asp at position 64 of SEQ ID NO: 1, a Lys at position 66 of SEQ ID NO: 1, and a Pro at position 69 of SEQ ID NO: 1;
(d) a Leu at positions 2, 62 and 70 of SEQ ID NO: 1, an Ala at position 44 of SEQ ID NO: 1, an Asp at position 64 of SEQ ID NO: 1, a Lys at position 66 of SEQ ID NO: 1, and a Pro at position 69 of SEQ ID NO: 1;
(e) a Leu at positions 2 and 62 of SEQ ID NO: 1, an Asp at position 64 of SEQ ID NO: 1, and a Lys at position 66 of SEQ ID NO: 1;
(f) a Leu at positions 2 and 62 of SEQ ID NO:1, a Ser at position 49 of SEQ ID NO: 1, an Asp at position 64 of SEQ ID NO: 1, and a Lys at position 66 of SEQ ID NO: 1;
(g) a Leu at one or more of positions 2, 62 and 70 of SEQ ID NO: 1, an Ala at position 44 of SEQ ID NO: 1, an Asp at position 64 of SEQ ID NO: 1, a Lys at position 66 of SEQ ID NO: 1, and a Pro at position 69 of SEQ ID NO: 1;
(h) a Leu at positions 2, 62 and 70 of SEQ ID NO: 1, an Ala at position 44 of SEQ ID NO: 1, an Asp at position 64 of SEQ ID NO: 1, a Lys at position 66 of SEQ ID NO: 1, and a Pro at position 69 of SEQ ID NO: 1;
(i) a Leu at positions 2, 62 and 70 of SEQ ID NO: 1, an Ala at position 44 of SEQ ID NO: 1, a Ser at position 49 of SEQ ID NO: 1, an Asp at position 64 of SEQ ID NO: 1, a Lys at position 66 of SEQ ID NO: 1, and a Pro at position 69 of SEQ ID NO: 1;
(j) a Leu at position 2 of SEQ ID NO: 1, a Thr at position 6 of SEQ ID NO: 1, an Asp at positions 8, 47 and/or 49 of SEQ ID NO: 1, a Met at positions 9 and/or 11 of SEQ ID NO: 1, a Ser at positions 14 and/or 66 of SEQ ID NO: 1, a Gly at position 46 of SEQ ID NO: 1, an Asn at position 68 of SEQ ID NO: 1, and a Lys at position 72 of SEQ ID NO: 1;
(k) a Tyr at position 4 of SEQ ID NO: 1, a Phe at positions 8 and/or 68 of SEQ ID NO: 1, an Ala at position 9 of SEQ ID NO: 1, an Arg at positions 10 and/or 49 of SEQ ID NO: 1, a Pro at position 12 of SEQ ID NO:1, a Glu at position 47 of SEQ ID NO: 1, a Met at position 48 of SEQ ID NO: 1, a Lys at positions 62 and/or 72 of SEQ ID NO: 1, an Asn at positions 63 and/or 73 of SEQ ID NO: 1, an Asp at position 64 of SEQ ID NO: 1, a Ser at position 74 of SEQ ID NO: 1, a Val at position 75 of SEQ ID NO: 1, and a Thr at position 76 of SEQ ID NO: 1;
(l) a Thr at position 6 of SEQ ID NO: 1, an Asp at positions 8, 47 and/or 49 of SEQ ID NO: 1, a Met at positions 9 and/or 11 of SEQ ID NO: 1, a Trp at position 10 of SEQ ID NO: 1, an Arg at position 12 of SEQ ID NO: 1, a Gly at position 46 of SEQ ID NO: 1, a Ser at positions 14 and/or 66 of SEQ ID NO: 1, an Asn at positions 68 and/or 72 of SEQ ID NO: 1;
(m) an Arg at positions 2 and/or 75 of SEQ ID NO: 1, an Ile at position 4 of SEQ ID NO: 1, a Phe at position 8 of SEQ ID NO: 1, a Met at position 9 of SEQ ID NO: 1, a Pro at position 12 of SEQ ID NO: 1, a Tyr at position 44 of SEQ ID NO: 1, a Ala at position 47 of SEQ ID NO: 1, a Ser at position 48 of SEQ ID NO: 1, a Leu at positions 68 and/or 74 of SEQ ID NO: 1, and a Val at positions 71 and/or 76; or
(n) the modifications as set forth in any one of (a)-(j), (1), or (m), and further comprising the following modification: Gly76 is absent or Gly75 and Gly76 are absent.

2. A polynucleotide encoding the polypeptide of claim 1 .

3. A cell or cell line comprising the polypeptide of claim 1 .

4. A composition comprising the polypeptide of claim 1 in admixture with a carrier, excipient or diluent.

5. A composition comprising the polypeptide of claim 1 and one or more of the following: 1) an inhibitor of RIF expression or activity or a CtIP compound that mimics constitutive phosphorylation; 2) one or more factors that maintain BRCA1-PALB2 interactions during the cell cycle; and, 3) one or more components of a gene editing system.

6. The composition of claim 5 , wherein the inhibitor of RIF expression or activity is an inhibitor of RIF1 expression or activity.

7. The composition of claim 5 , wherein the gene editing system is a CRISPR system.

8. A kit comprising the polypeptide of claim 1 .

9. A method of suppressing 53BP1 recruitment to DNA double-strand break sites in a cell comprising administering to the cell the polypeptide of claim 1 .

10. A method of increasing homologous recombination in a cell comprising administering to the cell the polypeptide of claim 1 .

11. A method of editing a gene in a cell using a CRISPR system comprising administering to the cell the polypeptide of claim 1 .

12. A method of increasing gene targeting in a cell comprising administering to the cell the polypeptide of claim 1 in combination with an inhibitor of DNA-PK.

13. A polypeptide comprising the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11.

14. A composition comprising the polypeptide of claim 13 in admixture with a carrier, excipient or diluent.

15. A composition comprising the polypeptide of claim 13 and one or more of the following: 1) an inhibitor of RIF expression or activity or a CtIP compound that mimics constitutive phosphorylation; 2) one or more factors that maintain BRCA1-PALB2 interactions during the cell cycle; and, 3) one or more components of a gene editing system.

16. A kit comprising the polypeptide of claim 13 .

17. The polypeptide of claim 13 comprising the amino acid sequence of SEQ ID NO: 9.

18. A method of increasing homologous recombination in a cell comprising administering to the cell the polypeptide of claim 13 .

19. A method of editing a gene in a cell using a CRISPR system comprising administering to the cell the polypeptide of claim 13 .

20. A method of increasing gene targeting in a cell comprising administering to the cell the polypeptide of claim 13 in combination with an inhibitor of DNA-PK.

21. A polynucleotide comprising the nucleic acid sequence of SEQ ID NO: 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 49 or 50.

22. A vector comprising the polynucleotide of claim 21 .

23. A kit comprising the vector of claim 22 and one or more of the following components: 1) an inhibitor of RIF expression or activity or a CtIP compound that mimics constitutive phosphorylation; 2) one or more factors that maintain BRCA1-PALB2 interactions during the cell cycle; and, 3) one or more components of a gene editing system.

24. A kit of claim 23 wherein the gene editing system is a CRISPR system.

Assignees

• Governing Council Univ Toronto
• Sinai Health Sys

Inventors

• Durocher Daniel
• Sidhu Sachdev
• Zhang Wei
• Sicheri Frank
• Canny Marella

Classifications

• C12N15/00

  Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N1/00, C12N5/00, C12N7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H4/00; new animals per se A01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00) · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C12N15/62

  DNA sequences coding for fusion proteins · CPC title

• C12N9/22

  Ribonucleases {[RNase]; Deoxyribonucleases [DNase]} · CPC title

• C12N2310/20

  involving clustered regularly interspaced short palindromic repeats [CRISPR] · CPC title